Cardiometabolic Disease and COVID-19: Risk, Treatment and Trials
Published: 13 July 2020
9m 40sPart 2 Metabolic Therapy Treatments
10m 46sPart 3 Phase III DARE-19 Trial
In this series, Mikhail Kosiborod and Hertzel Gerstein discuss the effects of Covid-19 and metabolic disease, early treatment with metabolic therapies and the Phase III DARE-19 Trial looking at dapagliflozin in Covid-19 patients.
Recorded remotely from Hamilton and Kansas City, 2020.
More from this programme
The Effect of COVID and Metabolic Disease and Early Treatment
Metabolic Therapy Treatments
|Metabolic Therapy Treatments||Watch now|
Phase III DARE-19 Trial
|Phase III DARE-19 Trial||Watch now|
Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.
He is also Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute. Dr Kosiborod is an internationally-recognised expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes.
Dr Kosiborod is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.
Hertzel C Gerstein
Dr Hertzel C Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences, where he holds the Population Health Institute Chair in Diabetes Research.